Review article: the therapy of gastrointestinal infections associated with the acquired immunodeficiency syndrome

C. M. WILCOX & K. E. MÖNKEMÜLLER

Department of Medicine, Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, Alabama, USA

Accepted for publication 29 December 1996

INTRODUCTION

Human immunodeficiency virus (HIV) infection remains a common world-wide infectious disease. Diseases of the gastrointestinal tract are among the most frequent complications of the acquired immunodeficiency syndrome (AIDS). Oesophageal disease occurs in 30–40% of patients, and the incidence of diarrhoea may be as high as 90%, particularly for patients with severe immunodeficiency.1–4 The incidence of some disorders has been unfavourably altered by the widespread use of prophylaxis for Pneumocystis carinii pneumonia.5–6 Over the last decade, greater experience with gastrointestinal disorders in these patients has resulted in a better appreciation of the spectrum of potential aetiologies, and an improved approach to evaluation and therapy. Fortunately, our therapeutic options have expanded due to the application of old drugs to new problems as well as through the development of newer agents. Nevertheless, truly effective therapy is still lacking for some opportunistic infections. This review will focus on the therapy and prophylaxis for the most common infections involving the gastrointestinal tract in HIV-infected patients (see Table 1).

CANDIDIASIS

Oropharyngeal and oesophageal candidiasis are common opportunistic infections in HIV-infected patients, and are frequently the initial manifestation of infection. Oropharyngeal candidiasis (thrush) is readily diagnosed by the characteristic white plaques which coat the buccal mucosa. Oropharyngeal candidiasis may occasionally present as diffuse erythaema without plaques or angular cheilitis.7 It is important to recognize the clinical spectrum of gastrointestinal diseases, as well as the appropriate and most cost-effective diagnostic strategies, as therapies for a number of these disorders are both widely available and highly effective. This review summarizes the major gastrointestinal infections which are seen in patients with the acquired immunodeficiency syndrome, and their treatment.
| Diagnosis          | CD4 count (*/mm³) | Clinical presentation                                                                 | Diagnosis                      | Treatment                          | Prophylaxis                      |
|--------------------|-------------------|--------------------------------------------------------------------------------------|-------------------------------|------------------------------------|----------------------------------|
| Candidiasis        |                   |                                                                                      | Clinical appearance           |                                    |                                  |
| Oropharyngeal any  |                   | Thrush (pseudomembranes), plaques (hyperplastic), erythema                           | Potassium hydroxide (KOH) prep test | Nystatin*                         | Primary: NR                      |
|                   |                   |                                                                                      |                               |                                    | Secondary: R for severe, recurrent |
|                   |                   |                                                                                      |                               |                                    | disease                          |
|                   |                   |                                                                                      |                               |                                    |                                  |
| Oesophageal < 300  | Dysphagia, odynophagia, patchy or circumferential white plaques                     | Endoscopy, biopsy, brushings       | Fluconazole*                   | Amphotericin B                    | Primary: R for recurrent disease  |
|                   |                   |                                                                                      |                               |                                    |                                  |
| CMV oesophagitis  < 100 | Odynophagia, dysphagia, oesophagospasm (chest pain), ulcers | Endoscopy, biopsy, immunohistochemistry, in situ hybridization, PCR | Ganciclovir*                   | Amphotericin B                    | Primary: R for CD 4 < 50 and seropositive for CMV |
|                   |                   |                                                                                      |                               |                                    | Secondary: R                    |
|                   |                   |                                                                                      |                               |                                    |                                  |
| CMV colitis < 100  | Abdominal pain, diarrhoea, fever, ulcers, submucosal petechiae, patchy colitis, ulcer | Endoscopy, biopsy, culture, immunohistochemistry, PCR, in situ hybridization | Ganciclovir*                   | Amphotericin B                    | Secondary: R                    |
|                   |                   |                                                                                      |                               |                                    |                                  |
| HSV stomatitis < 200 | Ulcers, vesicular lesions | Clinical appearance, cytologic smear ('giant cells'), culture, tissue biopsy | Acyclovir* | Acyclovir* | Primary: NR                      |
|                   |                   |                                                                                      |                               | Secondary: R if recurrent          |                                  |
|                   |                   |                                                                                      |                               |                                    |                                  |
| HSV oesophagitis  < 200 | Odynophagia, dysphagia, chest pain, deep ulcers, diffuse mucosal erosions | Oesophagoscopy, biopsy, 'intranuclear Cowdry type A inclusions' | Acyclovir* | Acyclovir* | Primary: NR                      |
|                   |                   |                                                                                      |                               | Secondary: R                      |                                  |
| Recto-anal HSV < 200 | Proctalgia, tenesmus, mucopurulent discharge | Anoscopy, sigmoidoscopy see above | Acyclovir* | Acyclovir* | Primary: NR                      |
|                   |                   |                                                                                      |                               | Secondary: R                      |                                  |
| Protozoa          |                   |                                                                                      |                               |                                    |                                  |
| Cryptosporidia < 180 | Watery diarrhoea, weight loss, abdominal cramps                              | Stool: modified AF stain, biopsy, electron microscopy | Paromomycin | Spiramycin, Azithromycin | Primary: NR | Secondary: R if CD 4+ < 100 |
|                   |                   |                                                                                      |                               |                                    |                                  |
| Microsporidia < 200 | Chronic watery diarrhoea, cholangitis, papillitis                               | Small intestinal biopsy (Giemsa, methylene blue) | Albenzole | Albenzole | Primary: NR                      |
|                   |                   |                                                                                      |                               |                                    | Secondary: NR |                                  |
| Isospora < 200     | Weight loss followed by profuse diarrhoea, nausea, abdominal pain, dehydration | Stool: modified trichrome           | TMP-SMX* | Sulphadione | Primary: NR                      |
|                   |                   |                                                                                      |                               |                                    | Secondary: R |                                  |
| Cyclospora any     | Watery diarrhoea, fatigue, anorexia                                            | Small bowel biopsy, acid-fast spasm | Pyrimethamine | Pyrimethamine | Not known |
general, determining the aetiologic species is unnecessary since therapy is the same.

Clinically, oesophageal candidiasis may be strongly suspected in the patient with thrush, moderately severe immunodeficiency (CD4 lymphocyte count < 200/mm³), and oesophageal symptoms. However, thrush may be absent in one-third of patients with oesophageal candidiasis. A definitive diagnosis rests on the identification of typical yeast forms in endoscopic mucosal biopsies or oesophageal brushings. The detection of Candida does not exclude other disorders, as Candida may coexist with other oesophageal processes in 14–25% of symptomatic patients.

### Therapy

Topical non-systemic therapy has been the mainstay of treatment for oropharyngeal candidiasis. Although nystatin is effective, clotrimazole troches have now largely replaced nystatin as the principal non-systemic agent used due to its ease of administration, palatability, negligible side-effects and drug interactions, and effectiveness. Clinical cure is seen in 65–94% of patients following 14 days of clotrimazole therapy.

The first oral systemic antifungal agent available for widespread clinical use was ketoconazole. This agent has a broad spectrum of antifungal activity which includes Coccidioides immitis, Histoplasma capsulatum and Blastomyces, has minimal efficacy for Cryptococcus and lacks activity against Mucormycosis and Sporothrix. It requires an acid milieu for absorption. Fluconazole, released in 1990, has a broader spectrum of antifungal activity than ketoconazole, including Cryptococcus. Excellent absorption, regardless of gastric pH, and long half-life (~30 h), make this an ideal oral antifungal agent. Importantly, the pharmacokinetics of fluconazole are similar in HIV-infected patients as compared to other immunocompromised hosts. Fluconazole is excreted solely in the urine; therefore, dose adjustments may be required in patients with renal insufficiency. Itraconazole is the newest oral systemic antifungal agent. Like fluconazole, it has a broad spectrum of antifungal activity, prolonged half-life and is well tolerated. Similar to ketoconazole, elevations in gastric pH retard absorption. Contrasts and comparisons between these agents are listed in Table 2.

Although local non-systemic therapy is effective, a number of trials have demonstrated a therapeutic advantage of systemic therapy for oropharyngeal
candidiasis in HIV-infected patients. Fluconazole has been shown to be superior to clotrimazole troches for oropharyngeal candidiasis.\(^{13, 14}\) The largest comparative trial\(^{14}\) suggested overall equivalency, although fluconazole-treated patients were more likely to have mycologic cure (65% vs. 48%) and had a lower rate of relapse at 2 weeks (82% vs. 50%); this relapse difference was equal at 1 month follow-up. Single-dose therapy with fluconazole 150 mg is as effective as a 7-day treatment course.\(^{18}\) Unlike oropharyngeal disease, non-systemic therapy (e.g. nystatin) is largely ineffective for oesophageal candidiasis. At most centres, fluconazole has become the drug of choice for oesophageal candidiasis. Randomized trials have shown fluconazole to be superior to ketoconazole for both oropharyngeal\(^{19, 20}\) and oesophageal candidiasis.\(^{21}\) In a prospective randomized trial, Laine and colleagues\(^{21}\) compared ketoconazole 200 mg/day to fluconazole 100 mg/day in 143 patients with AIDS and oesophageal candidiasis.

 Table 2. Comparisons of antifungal agents used to treat candidiasis

| Antifungal         | Presentation                          | Uses                  | Dose                                      | Side-effects                                      | Drug interaction     |
|--------------------|---------------------------------------|-----------------------|-------------------------------------------|---------------------------------------------------|----------------------|
| Nystatin           | Oral suspension pastilles             | Thrush                | 500 000–1000 000 U 3–5 every day × 14 days same dose | Oral irritation, diarrhoea, nausea, vomiting, urticaria | None                 |
|                    |                                       | Prophylaxis           |                                           |                                                   |                      |
| Clofibrateazole     | Troches, oral suspension              | Thrush                | 10 mg p.o. 5 × d × 14 days same dose      | Nausea, vomiting, pruritus, rash                  | None                 |
|                    |                                       | Prophylaxis           |                                           |                                                   |                      |
| Fluconazole         | Tablets, oral suspension, iv preparation | Oesophagitis (first line) | 200 mg p.o./followed by 100 mg p.o. until improvement (1–2 weeks) | Nausea, pruritus, headache, rash, seizures, hepatitis, alopecia, anaphylaxis, eosinophilia, nausea, vomiting, pruritus, rash | Sulphonylureas, Coumadin, Phenytoin, Rifampin, Theophylline, Cyclosporin |
|                    |                                       | Prophylaxis           | 50–100 mg p.o. q.day                      |                                                   |                      |
| Ketoconazole        | Tablets (take with cranberry juice or carbonated beverage), oral suspension | Oesophagitis | 200–400 mg p.o. q.d.s. × 1–2 weeks | Nausea, vomiting, anorexia, impotency, adrenal suppression, hepatitis, pruritus, decreased libido, hypocholestolemia, rash, gynecomastia | Coumadin, Rifampin, Prednisone, Contraceptives, Terfenadine, Astemizole, Cisapride, Didanosine, Theophylline, Midazolam, H\(_2\) blocker, Antacids, Cyclosporin, Phenytoin, Oral hypoglycemics, Digoxin, Same drugs as ketoconazole |
|                    |                                       | Prophylaxis           | 200 mg p.o. q.d.s.                        |                                                   |                      |
| Itraconazole        | Capsules, oral suspension             | Oesophagitis non-responsive to fluconazole | 200 mg p.o. q.d.s. × 14 days | Nausea, vomiting, pruritus, rash, hypokalemia, oedema, hypertension, SGOT elevation | Pentamidine, Aminoglycosides, Cyclosporin, Digitalis, Corticosteroids, Antineoplastics |
|                    |                                       |                       |                                           |                                                   |                      |
| Amphotericin B      | Lozenges, i.v. preparation, oral suspension | Oesophagitis, Disseminated candidiasis | 0.3–0.5 mg/kg q.d.s. × 7 days following 1 mg test dose | Nausea, vomiting, anaemia, hypomagnesaemia, renal failure, thrombophlebitis, hypokalemia, Nephrotoxic agents | Pentamidine, Aminoglycosides, Cyclosporin, Digitalis, Corticosteroids, Antineoplastics |

© 1997 Blackwell Science Ltd, *Aliment Pharmacol Ther* 11, 425–443
Endoscopic cure and symptom resolution were found in 91% and 85%, respectively, of fluconazole-treated patients, compared to 52% and 65%, respectively, for patients randomized to ketoconazole. Clinical cure paralleled endoscopic cure. Both drugs were well tolerated with very few side-effects. The response rate of oesophageal candidiasis with fluconazole tends to be very rapid, with most patients experiencing significant clinical improvement by 3–5 days.12, 22 Itraconazole 200 mg/day was found to be equivalent to ketoconazole 200 mg b.d. for oropharyngeal and oesophageal candidiasis.23 Another study24 found greater endoscopic cure at 3 weeks (75% vs. 38%) with fluconazole 100 mg b.d. compared to itraconazole 100 mg b.d., although no differences in short-term clinical remission (78% vs. 73%) were demonstrated. In the largest study reported to date, Barbaro et al.25 randomized 2213 AIDS patients with a first episode of Candida esophagitis to fluconazole or itraconazole. Clinical cure was achieved in 81% of fluconazole-treated patients compared to 75% of itraconazole-treated patients (P < 0.001), although there was no difference at the end of the follow-up period (96%). Approximately 25% of patients in both groups required an increase in dosage at 2 weeks.

Oral suspension forms of both fluconazole and itraconazole have recently been developed, and their efficacy appears similar to pill forms.26 Preliminary results of comparative trials between fluconazole pills and itraconazole suspension suggest equivalency.27 The suspension form is an attractive alternative to pills for patients with severe oesophageal symptoms, as well as for use in children. The additional cost of fluconazole and itraconazole over ketoconazole (∼2–3 times more expensive) may be a consideration, especially when the disease is mild and non-life-threatening (e.g. mild thrush). Monotherapy with flucytosine at 100 mg/kg/day orally was found to be inferior to fluconazole for the treatment of oesophageal candidiasis.28

Amphotericin B is highly effective against all Candida species. Because of its toxicity, this drug is used almost exclusively in patients with thrush and/or oesophageal candidiasis with clinical and/or microbiologically resistant Candida. Although large studies evaluating the efficacy of amphotericin B for oesophageal candidiasis in AIDS have not been conducted, clinical experience suggests this agent is highly effective. The use of intralipid with amphotericin B infusion may reduce some of the side-effects.29, 30 Low doses of amphotericin B (0.5 mg/kg/day for 7–10 days) are usually adequate therapy for oropharyngeal and oesophageal candidiasis. The availability of a new lipid formulation (liposomal amphotericin B) reduces the side-effects and toxicity and maintains efficacy, although at a markedly increased cost.31 A suspension form of amphotericin B for oral use is now commercially available, and may find its greatest utility in patients with resistant thrush.32

Resistance

An emerging problem of significant concern is the development ofazole resistance. A number of studies of both oropharyngeal and oesophageal candidiasis have now documented clinical and microbiological resistance to these azole agents, most notably fluconazole.31, 34 Testing of Candida isolates from patients with AIDS have found resistance in up to 33%,35–37 The mechanism(s) for drug resistance are incompletely understood. Risk factors for resistance include prior use of azole drugs including total dosage, severe immunodeficiency (CD4 lymphocyte count < 100/mm³), and recurrent episodes of candidiasis.27–29 Some patients may harbour resistant strains without any prior azole therapy.35 In vitro resistance correlates with clinical resistance.38, 40–43 With prolonged azole use, there may be selection of a single resistant strain44, 46 as well as an increase in non-albicans strains,8 which are inherently more resistant to these drugs.46 Despite an increase in MIC, clinical response to fluconazole is usually maintained regardless of high-level resistance.37 With fluconazole resistance, the MIC to other azoles, such as itraconazole, may also increase;36 resistance to one azole therefore suggests cross-resistance to others.47 Although most fluconazole-resistant strains remain susceptible to itraconazole, there is an upward shift of the MIC to itraconazole, which may result in a poor clinical response. Return of sensitivity to fluconazole has been noted following drug discontinuation.34 It is unclear whether intermittent azole use leads to greater resistance than continued drug administration.49

Mild drug resistance can often be overcome with increases in the dosage of the antifungal agent; up to 800 mg/day of fluconazole have been used. If higher doses are clinically ineffective or cause side-effects, switching to another azole can be tried; if there is no response, amphotericin B is effective. Microbiological and clinical resistance to amphotericin B is very rare. Nystatin or clotrimazole may occasionally be effective in...
patients with oropharyngeal candidiasis and clinical resistance to systemic azole agents. Combination therapy of flucytosine with azoles for drug resistance has not been well studied. Until further studies are available which clarify the mechanisms of drug resistance, it appears prudent to limit the use of azoles where possible.

Prophylaxis

Despite the frequency of oropharyngeal and oesophageal candidiasis in HIV-infected patients, primary prophylaxis is not widely administered, because these disorders are non-life-threatening, therapy is very effective, and there is concern that widespread use of primary prophylaxis will exacerbate the problem of drug resistance. Both non-systemic and systemic therapies provide effective prophylaxis. Whereas primary prophylaxis for Candida is rarely provided, secondary prophylaxis is commonly given, especially for patients with multiple recurrences. Fluconazole 50–100 mg/day or 150 mg once weekly are effective prophylaxis against recurrent oropharyngeal and oesophageal candidiasis. The use of fluconazole as prophylaxis has not shown a survival benefit. An additional benefit of chronic azole therapy is a reduction in the incidence of systemic cryptococcosis.

VIRAL DISEASES

Cytomegalovirus

Cytomegalovirus (CMV) is one of the most common opportunistic infections in patients with AIDS. Clinical and/or autopsy evidence of CMV disease may be observed in up to 90% of these patients, and antibody positivity to CMV is present in 90% of homosexual men and 70% of intravenous drug users. In fact, recent studies have shown an increasing incidence of CMV disease paralleling the widespread use of prophylaxis for Pneumocystis carinii pneumonia. CMV disease typically occurs when immunodeficiency is severe (CD4 lymphocyte count < 100/mm³); in these patients, the incidence of disease may approach 21% at 2 years. Although the retina is the most common target for CMV, gastrointestinal involvement remains important because of its frequency and morbidity. The diagnosis of CMV disease is best established by identification of viral cytopathic effects (inclusions) in gastrointestinal mucosal biopsies; viral culture of biopsy specimens is less sensitive and specific.

Therapy. Treatment for gastrointestinal CMV disease is limited to intravenous therapy with ganciclovir, foscarnet, and more recently, cidofovir (Table 3). These drugs have similar mechanisms of antiviral action, including inhibition of viral DNA polymerases. In addition to the anti-CMV effects, foscarnet, and possibly ganciclovir, also have an inhibitory effect on HIV. A number of open-label trials of ganciclovir for HIV-infected patients with gastrointestinal CMV disease have demonstrated clinical improvement in ∼75% of patients. Open-label trials of foscarnet have yielded comparable results. The only placebo-controlled trial of ganciclovir, which evaluated colitis, found no clinically significant differences, probably because the treatment period was only 2 weeks. A randomized trial comparing ganciclovir to foscarnet in 48 AIDS patients with gastrointestinal CMV disease found similar clinical efficacy (73%) regardless of the location of disease (oesophagus vs. colon), with endoscopic improvement documented in over 80%. Time to progression of disease was similar (13–16 weeks) regardless of the use of maintenance therapy. Side-effects occurred in half the patients in each group.

Ganciclovir has a significant inhibitory effect on haematopoiesis; leukopenia occurs in up to 40% with long-term use and is more severe when concomitant drugs which affect the bone marrow are given, such as azidothymidine (AZT). The use of growth-stimulating factors will usually restore cell counts toward normal, permitting continued drug administration. In contrast to ganciclovir, foscarnet has no myelosuppressive effects, but causes renal insufficiency and disturbances in calcium, phosphorus and magnesium homeostasis. Foscarnet is an anionic compound that binds divalent cations, such as calcium and phosphorus, which accounts for the metabolic effects on these cations. Adjustments in dosage based on creatinine clearance, and the intravenous administration of isotonic saline prior to and during foscarnet infusion help prevent renal insufficiency. When symptomatic, electrolyte disturbances may be treated by oral supplementation. Coadministration of foscarnet with intravenous pentamidine should be avoided given the similar effects on calcium homeostasis. Similarly, drugs which cause renal insufficiency such as amphotericin B and aminoglycosides should be used cautiously when administering...
foscarnet. Genital ulceration in both males and females has been reported, and appears to be due to exposure of these tissues to high urinary concentrations of foscarnet. The newest agent released for the treatment of CMV disease is cidofovir. This drug is a nucleotide analogue with activity against all herpes viruses; it has a very long half-life and can be given once weekly. It must be given with probenecid to prevent renal insufficiency. To date this drug has been tested exclusively in patients with retinal disease, but future studies assessing efficacy for gastrointestinal CMV disease are anticipated.

The efficacy, tolerability and cost of ganciclovir have established it as first line therapy for gastrointestinal CMV disease in AIDS. Our current policy for the therapy of gastrointestinal CMV disease is to administer intravenous ganciclovir, assuming there are no major contraindications to this agent such as pancytopenia. We treat with induction doses for 2–4 weeks, depending on the clinical and endoscopic response. In our experience, oesophageal disease tends to respond more rapidly than does colonic disease. Endoscopic re-examination following therapy is important for those patients with persistent symptoms. Ophthalmological examination is mandatory at the time of diagnosis in all patients to exclude retinal disease; long-term drug administration will be necessary in these patients. Failure to respond to ganciclovir may be the result of low serum levels or drug resistance. 62 For patients with major contraindications to ganciclovir or in whom bone marrow stimulating factors are ineffective, foscarnet should be given. If a patient does not respond to ganciclovir (and the diagnosis is well established), foscarnet is usually effective. 68, 77 Combination therapy of foscarnet and ganciclovir appears to be effective for ganciclovir failures and has been used as primary therapy. 78, 79 (See Table 3 for comparisons between ganciclovir and foscarnet.)

Table 3. Comparisons between ganciclovir and foscarnet

| Drug          | Mechanism of action                                      | Presentation                     | Dose                          | Adverse effects                  | Drug interactions |
|---------------|----------------------------------------------------------|----------------------------------|-------------------------------|----------------------------------|-------------------|
| Ganciclovir   | Prodrug, phosphorylated intracellularly to triphosphate by viral enzymes. Inhibits viral DNA polymerase | i.v. preparation: 10 mL sterile vial (500 mg each)* p.o. tablets in (500 mg each) | (i) Induction: 5 mg/ kg q.d.s. 12 h × 14–21 days (ii) maintenance 5 mg/ kg q.d.s. or 6 mg/ kg q.d.s. × 5 days every week | Myelosuppression Granulocytopenia* Anaemia Seizures* Abnormal LFTs Headache Confusion Seizures Renal tubular acidosis | Probenecid Zidovudine Imipenem Dapsone Pentamidine Flucytosine Amphotericin Vincristine Adriamycin |
| Foscarnet     | Inhibits viral DNA polymerases and transcriptase          | i.v. preparation 250 and 500 mg bottles | (i) Induction 90 mg/ kg 12 h or 60 mg/ kg q.d.s. 8 h × 2–3 weeks* | Renal failure* Hypophosphatemia Hypocalcemia Hypokalemia Hypomagnesemia Hyperphosphatemia Anaemia* Seizures | Aminoglycosides Amphotericin Drugs that induce hypocalcemia |
| (Foscavir)    |                                                          | (ii) maintenance 90–120 mg/kg/day |                               |                                  |                   |

* Do not refrigerate after reconstitution (may precipitate).
* Store capsules at 15–30 °C.
* G-CSF administered subcutaneously, 1–8 μg/kg/day, for ganciclovir-induced neutropenia.
* Especially if combined with imipenem.
* Response may be evident in up to 6 weeks.
* Leukopenia and thrombocytopenia are uncommon.
* Administer one litre of normal saline prior to the infusion.

foscarnet. Genital ulceration in both males and females has been reported, and appears to be due to exposure of these tissues to high urinary concentrations of foscarnet. The newest agent released for the treatment of CMV disease is cidofovir. This drug is a nucleotide analogue with activity against all herpes viruses; it has a very long half-life and can be given once weekly. It must be given with probenecid to prevent renal insufficiency. To date this drug has been tested exclusively in patients with retinal disease, but future studies assessing efficacy for gastrointestinal CMV disease are anticipated.

The efficacy, tolerability and cost of ganciclovir have established it as first line therapy for gastrointestinal CMV disease in AIDS. Our current policy for the therapy of gastrointestinal CMV disease is to administer intravenous ganciclovir, assuming there are no major contraindications to this agent such as pancytopenia. We treat with induction doses for 2–4 weeks, depending on the clinical and endoscopic response. In our experience, oesophageal disease tends to respond more rapidly than does colonic disease. Endoscopic re-examination following therapy is important for those patients with persistent symptoms. Ophthalmological examination is mandatory at the time of diagnosis in all patients to exclude retinal disease; long-term drug administration will be necessary in these patients. Failure to respond to ganciclovir may be the result of low serum levels or drug resistance. For patients with major contraindications to ganciclovir or in whom bone marrow stimulating factors are ineffective, foscarnet should be given. If a patient does not respond to ganciclovir (and the diagnosis is well established), foscarnet is usually effective. Combination therapy of foscarnet and ganciclovir appears to be effective for ganciclovir failures and has been used as primary therapy. (See Table 3 for comparisons between ganciclovir and foscarnet.)

If retinal disease is absent and a complete symptomatic and endoscopic response is documented following induction therapy, we stop therapy and look for recurrent symptoms. The relapse rate for oesophageal and colonic
disease is similar (30–50%). For those patients with frequent relapses of gastrointestinal disease, long-term once-daily maintenance intravenous administration is appropriate. There are no data regarding the efficacy of oral ganciclovir for either maintenance therapy or treatment of acute gastrointestinal disease.

**Prophylaxis.** Oral ganciclovir has been recommended for primary prophylaxis when immunodeficiency is severe (CD4 count < 100/mm³), given the incidence of disease in this setting. The oral absorption of ganciclovir is poor, with a bioavailability of 6–9%. The half-life of oral ganciclovir (3–7.3 h) is similar to intravenous administration (5 mg/kg); however, serum drug levels are much less (0.5 µg/mL) than those achieved with intravenous therapy (4.5–10 mg/mL). Oral ganciclovir occasionally causes bone marrow suppression.

Randomized placebo-controlled studies of oral ganciclovir for primary prophylaxis have demonstrated a reduction in the incidence of retinal and gastrointestinal involvement. In one study, the incidence of CMV disease at 1 year was 14% in the treated group compared to 26% in the placebo group. The number of patients developing gastrointestinal CMV was low in both groups. The development of resistance is a concern with long-term use of oral ganciclovir. Nevertheless, studies to date have shown resistance to be rare with either oral or intravenous administration. Resistance to foscarnet has not been extensively studied.

**Herpes simplex virus**

Herpes simplex virus (HSV) is an uncommon gastrointestinal pathogen in HIV-infected patients, in contrast to other immunocompromised patients. Since HSV primarily infects squamous mucosa, oropharyngeal, oesophageal and perianal involvement are the most common sites of disease. Oropharyngeal disease may be isolated, or may occur in association with oesophageal disease. In a large prospective study of 100 HIV-infected patients with ulcerative oesophagitis, HSV oesophagitis was identified in only 5%, whereas the prevalence of CMV disease was almost 50%. Like CMV, the incidence of HSV disease increases as immunodeficiency worsens, with the greatest frequency occurring when the CD4 count is < 100/mm³. Mucosal biopsy is the most specific diagnostic method; cytology and culture also appear to be reliable techniques.

For the patient with mild to moderate disease who is able to tolerate pills, oral administration of acyclovir 15–30 mg/kg/day is effective. Absorption of oral acyclovir is inconsistent and may be <30%; thus for patients with more severe disease, a higher dose may be required. Intravenous administration should be used when severe odynophagia limits oral intake or when the patient has not responded to high-dose oral therapy. In general, resistance is defined clinically as progression of disease despite acyclovir therapy. Although uncommon, acyclovir resistance has been documented, and is usually caused by a mutation in the thymidine kinase gene. The incidence of acyclovir resistance during long-term therapy is unknown. In patients who are not immunocompromised, in vitro resistance can usually be overcome by increasing doses, whereas immunocompromised patients usually require an alternative therapy. Ganciclovir, foscarnet and famciclovir are also highly effective against HSV; foscarnet is the preferred therapy for acyclovir resistance. Foscarnet resistance has also been reported following long-term therapy for HSV. The relapse rate of gastrointestinal disease is not well defined, but is probably similar to CMV. Primary prophylaxis is not currently recommended; secondary prophylaxis is usually provided for patients with genital disease or those with frequent relapses of oropharyngeal or oesophageal disease.

**Other viral diseases**

A number of other viral pathogens have been reported to involve the gastrointestinal tract in patients with AIDS. Epstein–Barr virus has been described as a cause of oesophageal ulcer. Rotavirus has been linked to both acute and chronic diarrhoea. Adenovirus has been reported to cause diarrhoea and colitis. Several unusual viruses have been identified in HIV-infected patients with chronic diarrhoea, including astrovirus and picobirna virus and coronavirus. Although the true incidence of these viruses as gastrointestinal pathogens is unknown, it is probably low, and therapy is not currently available.

**Protozoa**

The emergence of the AIDS epidemic has greatly expanded the spectrum of gastrointestinal protozoal infections. Unlike fungi and viruses, these pathogens primarily involve the small intestine. As such, they play...
the greatest role as causative agents of diarrhoea. These pathogens may also infect biliary epithelium, resulting in the AIDS cholangiopathy syndrome.95, 96

Cryptosporidia

In most series, Cryptosporidium parvum is the most common protozoal infection causing diarrhoea, identified in up to 11% of symptomatic patients.97 Although a cause of acute diarrhoea, cryptosporidiosis is most commonly found in HIV-infected patients with chronic diarrhoea. Outbreaks of cryptosporidiosis are well described in both immunocompetent and immunodeficient hosts and result from contamination of public water sources.98, 99 In contrast to immunocompetent patients with cryptosporidiosis, where spontaneous cure is uniform, the natural history is much more variable in HIV-infected patients.100 This variability is due to the effect of immunodeficiency, as patients with CD4 lymphocyte counts > 180/mm³ usually have a self-limited illness,101 whereas in patients with a CD4 count < 50/mm³, the disease is often devastating, resulting in severe malabsorption, electrolyte disturbances, dehydration and weight loss, with a median survival of <12 weeks.102 The pathogenesis of mucosal injury is poorly understood, although the degree of architectural distortion (villous atrophy) and inflammation are related to the parasite burden.102

Therapy. Over 60 therapies have been used for the treatment of intestinal cryptosporidiosis, most without success.103 Several case reports suggest that immune reconstitution, either through potent antiretroviral therapy104 or improvements in nutritional status,105 may result in a clinical remission. A novel therapy includes the use of bovine colostrum. This consists of a concentrate of immunoglobulin prepared from bovine colostrum following immunization with cryptosporidial antigens;106, 107 case reports have demonstrated clinical improvement in 50% of patients following the use of bovine colostrum. The results of an open-label trial108 found a reduction in stool frequency and weight in patients receiving the powder (but not pill) formulation of bovine immunoglobulin, although less than half of the patients had a 50% reduction in stool weight or clearance of the pathogen from the stool.108 Letrazuril, a drug with activity against coccidia, was found to have some efficacy in two studies.109, 110

The most effective agent currently available for the treatment of cryptosporidiosis is paromomycin. This non-absorbable111 oral aminoglycoside agent has previously been used for the treatment of other parasitic diseases, but its mechanism of action for cryptosporidiosis is unknown. In vitro models using a human enterocyte cell line suggest an antimicrobial effect,112 whereas a study using cryptosporidia in culture did not demonstrate sensitivity with this agent.113 Case reports and small open-label trials of paromomycin have documented response rates up to 100%.103, 114±116 In a study of 35 patients, a complete response was seen in 20% of patients, with a partial response observed in an additional 43%;116 responders had higher preserved immune function as assessed by CD4 count. In a prospective open-label trial of 24 patients, 22 (92%) had a clinical response, with a complete remission observed in 18.115 In the 22 responders, clearance of the organisms was noted on follow-up stool studies and/or small bowel biopsy. Other studies, however, have found persistent oocyst excretion, despite clinical improvement.114 The efficacy of paromomycin was best shown in a randomized double-blind placebo-controlled crossover trial of 10 patients, where both stool frequency and oocyst excretion were significantly reduced with paromomycin as compared to placebo.117 Although the available literature supports the use of this agent, in our experience and others,99 those patients with the most severe disease (and most severe immunodeficiency) are the least likely to respond. If the CD4 count is >200/mm³, drug discontinuation after clinical cure is appropriate with close follow-up. For those patients with a CD4 count < 100/mm³ in whom therapy is clinically effective, long-term administration is required to prevent relapse. Nevertheless, despite continued therapy, relapse may still occur.115

Microsporidia

Over the last decade, microsporidia have gained global attention as gastrointestinal pathogens in both immunodeficient and immunocompetent patients. Intense investigation has demonstrated that these parasites are common intestinal and biliary pathogens in patients with AIDS.118±120 Microsporidia are a heterogeneous group of obligate intracellular spore-forming (coccidian) protozoa which may involve a variety of organ systems causing either localized or disseminated disease.121, 122 The environmental source and mode of transmission of
these pathogens are unknown. Six microsporidial genera have been linked to human disease; gastrointestinal disease has been reported from only two of these, *Enterocytozoon biensis* and *Encephalitozoon intestinalis*: *E. biensis* is the cause of most cases of gastrointestinal disease.\(^{121}\) Coinfection with these two microsporidia or with other pathogens has been reported.\(^{123}\) In some studies of HIV-infected patients, microsporidia are the most commonly identified pathogen. Kotler and Orenstein\(^{119}\) found microsporidia in 39% of AIDS patients undergoing gastrointestinal evaluation for diarrhoea. This high prevalence is probably not related to an increasing incidence of disease, but rather to greater recognition and improved diagnostic testing. Although electron microscopy of small bowel biopsies is considered the gold standard for diagnosis, recent studies have shown haematoxylin and eosin, brown-brenn, Giemsa, or modified trichrome staining of small bowel biopsies to have sensitivities of 77–83% with specificities approaching 100%,\(^{121, 124}\) large comparative trials of stool testing with small bowel biopsy are lacking.\(^{125}\) Immuno-fluorescent stains are being developed and are likely to provide additional sensitivity over current stool testing methods.

**Therapy.** Treatments for microsporidia are variably effective. Initial studies of metronidazole demonstrated some efficacy,\(^{126}\) although our experience, as well as others,\(^{127}\) has shown this agent to be largely ineffective. Atovaquone showed some efficacy in a small open-label trial.\(^{128}\) Albendazole, an anti-helminthic drug, has shown promise in open-label trials,\(^{129–131}\) with response rates of \(\approx 50\%\). Despite clinical improvement, the organisms persist in the stool and on small bowel biopsy.\(^{130}\) In contrast, studies of patients with *E. intestinalis* show response rates to albendazole of 66–100%, with some patients having clearance of the organism,\(^{127, 130}\) and no relapse.\(^{130}\) With the recognition that two microsporidial species involve the bowel, it has become clear that albendazole is highly effective for *E. intestinalis* but largely ineffective for *E. biensis*. This response difference emphasizes the importance of a species-specific diagnosis of intestinal microsporidiosis. Currently, albendazole is only available on a compassionate basis from SmithKline. Prophylactic studies for microsporidia have not been performed and are unlikely to be initiated given the variable geographical prevalence and lack of a widely available effective therapy for *E. biensis*.

**Isospora**

*Isospora belli* is a rare gastrointestinal pathogen in HIV-infected patients in the US, whereas it is endemic in many developing countries such as Haiti,\(^{122}\) and is a major cause of chronic diarrhoea. As with other protozoa, it is primarily a small bowel pathogen. The diagnosis is best established by modified acid-fast stool staining;\(^{122}\) small bowel biopsy may also be diagnostic. In contrast to cryptosporidia and microsporidia, effective therapy is available. Trimethoprim–sulphamethoxazole results in a cure in most patients. The relapse rate is unknown. The widespread use of trimethoprim–sulphamethoxazole prophylaxis for *Pneumocystis carinii* may be one explanation for the low incidence of this infection in developed countries.

**Cyclospora**

Cyclospora, another coccidian protozoa, have recently been recognized throughout the world as gastrointestinal pathogens both in immunocompetent patients and patients with AIDS.\(^{131, 132}\) The prevalence of cyclospora in both developed and developing countries is unknown. A number of similarities exist in the microbiology, epidemiology and clinical expression of cyclospora and cryptosporidia. Cyclospora have a similar morphological appearance to cryptosporidia, although larger in size (8–10 \(\mu m\) vs. 4–6 \(\mu m\), respectively).\(^{131}\) These pathogens are difficult to appreciate on routine microscopy of small bowel biopsies, although electron microscopy is often diagnostic. Since trimethoprim–sulphamethoxazole is a highly effective therapy,\(^{132}\) the frequency of cyclospora in developed countries is likely to be low.

**Giardia**

Giardia species, including *Giardia lamblia*, have no increased prevalence in HIV-infected patients, and the clinical presentation and diagnostic methods are also similar to HIV-seronegative patients. It is well recognized that multiple stool tests obtained on different days may be required for diagnosis as intestinal shedding is sporadic.\(^{133}\) Light microscopic detection of giardia cysts and, less frequently, trophozoites, continues to be the mainstay of diagnosis. Fresh stool specimens should be examined or fixed with polyvinyl alcohol formalin and then stained with trichrome or iron haematoxylin. Cyst detection can be improved by the use of immunofluores-
Entamoeba dispar represent pathogens (e.g. diarrhoea, suggesting that in most patients these do not stool, treatment has not been shown to reliably cure addition, despite clearance of these protozoa from the infected patient with diarrhoea and amoebic cysts. In causes is always appropriate in a symptomatic HIV-immunocompromised patients, suggesting that a search for other potential pathogens, might cause significant disease in immunocompromised patients. Indeed, the mean CD4 lymphocyte count in patients with MAC is 60/mm$^3$. Although Mycobacterium tuberculosis can present in an atypical fashion in HIV-infected patients, gastrointestinal involvement remains rare, especially in developed countries. MAC has rarely been reported to involve the oesophagus, biliary tree and colon: small intestinal disease is the most common site of luminal gastrointestinal involvement. The pathogenesis of MAC is believed to be ingestion of mycobacteria with subsequent small intestinal infection, followed by widespread dissemination. Nevertheless, autopsy studies of AIDS patients with MAC bacteremia may fail to identify any foci of disease in up to 30% of patients. The liver and spleen are the most common sites for dissemination. Small bowel involvement is often diffuse. Massive infiltration of the small bowel, mimicking Whipple’s disease, has been described, and may account for the severe malabsorption seen in some patients. Although diarrhoea is common, systemic symptoms and signs of fever and wasting often dominate the clinical presentation. Positive blood cultures establish the diagnosis of disseminated MAC, but does not prove active gastrointestinal disease. In those with suspected disease, blood cultures may be negative, necessitating repetitive cultures, bone marrow biopsy or empirical therapy. The presence of a positive stool culture suggests, but does not prove, gastrointestinal involvement; stool culture positivity is a marker for subsequent disseminated disease.

**Therapy.** Therapy for MAC has improved substantially over the last decade. Previously used multi-drug regimens were poorly tolerated, associated with significant side-effects, and had low efficacy. More recently, dual therapy with clarithromycin and ethambutol has been shown to reduce bacterial load and provide clinical benefit. In general, single-agent
therapy is insufficient and frequently leads to resistance. Clarkethromycin appears to be the most effective single agent; ethambutol is also effective. A combination of rifabutin, ethambutol and clarithromycin was shown to be superior to rifampin, ethambutol, clofazazine and ciprofloxacin; bacteremia was cleared at 1 month in 78% of those receiving three drugs as compared to 40% in the four-drug regimen; survival was also significantly greater with the three-drug regimen (8.6 vs. 5.2 months, respectively). Relapse at 16 weeks was not seen in the three-drug group, suggesting the absence of resistance. Lifelong therapy is often given if a patient responds, because clearance of bacteria does not prove cure, as complete eradication is probably never achieved.

Depending on the clinical setting, there may be initial concern over the possibility of Mycobacterium tuberculosis in some patients. Multidrug regimens are effective for M. tuberculosis with microbiological and clinical cure observed at 9 months, provided drug resistance is not present; long-term therapy is thus unnecessary.

Prophylaxis. Rifabutin was the first agent studied for MAC prophylaxis. Placebo-controlled trials of this agent found a reduction in incidence of bacteremia and improvement in some clinical parameters, but no differences in survival. Based on this evidence, rifabutin was recommended for AIDS patients with CD4 count < 50/mm³. More recently, prophylaxis trials have compared clarithromycin to placebo, and azithromycin to rifabutin vs. the combination of these two agents. These studies show clarithromycin to be highly effective as monotherapy with a 6 month incidence of infection of 6% as compared to 16% for placebo. Of the 19 patients developing infection, 11 (58%) had clarithromycin-resistant strains. In the other study, azithromycin was found to be superior to rifabutin, with the combination regimen most effective. However, side-effects were significantly more common with the multidrug regimen (15.3% vs. 6% vs. 2.3%). As with the previous study, patients developing clinical disease while on azithromycin had developed in vitro resistance. These studies in combination suggest that the preferred therapy for prophylaxis should consist of a macrolide antibiotic, probably clarithromycin 500 mg b.d. Because of side-effects and drug interactions with dual therapy including rifabutin, monotherapy is appropriate for prophylaxis. Nevertheless, resistance commonly develops.

BACTERIA
Unusual presentations of common bacterial diseases became apparent early in the AIDS epidemic where Salmonella sp. or Campylobacter sp. bacteremia were reported as initial manifestations of AIDS. Bacteria were frequently identified in earlier studies of diarrhoea in HIV-infected patients. Currently, the prevalence of these infections as causes of diarrhoea are not well known, although are probably lower than in the past given the use of trimethoprim–sulphamethoxazole for prophylaxis. The spectrum of bacterial causes of diarrhoea and clinical presentation in AIDS are similar to immunocompetent patients. Blood and/or stool cultures are usually diagnostic; blood cultures may be positive when stool cultures are negative. Colitis may be identified by flexible sigmoidoscopy; mucosal biopsies should be performed in severely immunocompromised patients as CMV colitis may appear endoscopically similar. The role of enteroadherent E. coli as a cause of diarrhoea is unknown.

Clostridium difficile colitis is an important cause of diarrhoea in HIV-infected patients. A high frequency of C. difficile colitis would be anticipated in these patients, given the prevalence of antibiotic use and frequent hospitalizations—both factors which have been linked to C. difficile disease. In the appropriate clinical setting, detection of C. difficile toxin is diagnostic. Faecal leucocytes are usually present (60%) and are an important clue to the diagnosis. Flexible sigmoidoscopy is warranted in the patient in whom the disease is suspected but stool toxin is negative.

The clinical presentation and response to therapy of C. difficile colitis are no different in HIV-infected as compared to uninfected patients. Metronidazole, which can be administered either orally or intravenously, represents first line therapy. Vancomycin should be reserved for those patients with contraindication to or failure with metronidazole or when the disease is life-threatening: this agent is only effective when administered orally. Clinical cure can be obtained in essentially all patients. The relapse rate appears to be similar in HIV-infected as compared to uninfected patients.

IDIOPATHIC OESOPHAGEAL ULCER
An important entity not clearly linked to a specific infection is the HIV-associated idiopathic oesophageal ulcer (IEU). These lesions can present at the time of
seroconversion, although typically occur when immunodeficiency is severe; the median CD4 count in these patients is <50/mm³. Several studies have identified HIV-infected inflammatory cells in the ulcer base of these lesions, suggesting an aetiological role for HIV. However, HIV has not been identified in oesophageal squamous mucosa but rather in inflammatory cells, and has been found in HIV-infected patients with oesophageal diseases other than IEU. These lesions present similarly to ulcerative oesophagitis from other causes; severe odynophagia is almost uniformly present. IEU are almost as common as CMV oesophagitis in patients with AIDS, comprising ≈40% of oesophageal ulcers in these patients. The diagnosis is one of exclusion; CMV oesophagitis and IEU are indistinguishable clinically, radiographically and endoscopically.

**Therapy.** Treatment of HIV-associated IEU is rewarding. Prospective studies have documented healing rates of over 90% with oral corticosteroids. The regimen most commonly employed is prednisone 40 mg/day decreasing to 10 mg/week for a 1 month treatment course. Shorter courses of therapy may be effective for smaller ulcers. Although beneficial, intralausal injection of corticosteroids should be considered as second line therapy. The side-effects of corticosteroids are well recognized; patients with AIDS may be more likely to develop CMV disease while on therapy. Because oropharyngeal and/or oesophageal candidiasis may complicate steroid use and confuse the therapeutic response, we routinely use short courses of azole therapy with prednisone. The response to corticosteroids is rapid, with most patients experiencing significant pain relief within days. Although not as well studied, thalidomide also appears to be highly effective for IEU. Its mechanism of action is unknown, but it has been suggested that it is an inhibitor of tumour necrosis factor-α production. In doses of 200–300 mg/day, thalidomide has been documented to result in a clinical response rate and endoscopic cure in over 90% of treated patients. Thalidomide is well tolerated, with the main side-effect being somnolence; administration of the drug at bedtime tends to overcome this. Peripheral neuropathy and skin rash have also been seen. The major fear with thalidomide is the inadvertent use in the first trimester of pregnancy, which consistently results in severe birth defects. Thus, most would not use this agent in women of child-bearing age, unless the patient is surgically sterile. Both prednisone and thalidomide are similarly effective for oropharyngeal aphthous ulcerations. The relapse rate of IEU is ≈40–50% regardless of therapy.

**SYMPTOMATIC THERAPY OF DIARRHOEA**

For patients in whom antimicrobial therapy is ineffective or no specific cause for diarrhoea is found, symptomatic therapy will be necessary. When the diarrhoea is mild, bulking agents, bismuth or Kaopectate may provide relief. With more severe diarrhoea, medications to reduce intestinal transit are required. We routinely use diphenoxylate (Lomotil) in doses up to 10 tablets/day. Larger doses may cause anticholinergic side-effects, because diphenoxylate is combined with atropine in Lomotil. Despite the potential for abuse, narcotic agents are also highly effective. In patients with severe diarrhoea, tincture of opium (paregoric) is very effective. It is usually provided with a dropper which provides a morphine concentration of 0.4 mg/mL. The normal dose is 5–10 mL/day in divided doses, and the dose can be titrated up to 20 mL/day. Some patients may experience somnolence or abdominal cramps; these tend to dissipate over time. Octreotide, a somatostatin analogue, is an antisecretory agent with a variety of inhibitory functions throughout the gastrointestinal tract. Initial studies in patients with AIDS found this drug to provide effective control of diarrhoea in 50%. However, a large randomized placebo-controlled trial failed to demonstrate efficacy of this agent in patients with and without identifiable pathogens. The drug is given subcutaneously in doses of 50–100 μg t.d.s. Side-effects include decreased biliary motility (gallstones), diabetes and steatorrhea, the latter of which may potentially exacerbate diarrhoea. Although the drug has not been clearly proved to be effective, its use may be attempted in patients with severe diarrhoea requiring hospitalization (e.g. cryptosporidia). We consider a clinical response to be a reduction in stool frequency/volume of at least 50%.

**ACKNOWLEDGEMENTS**

No financial support was provided for this study.
REFERENCES

1. Connolly GM, Hawkins D, Harcourt-Webster JN, et al. Oesophageal symptoms, their causes, treatment, and prognosis in patients with the acquired immunodeficiency syndrome. Gut 1989; 30: 1033–9.

2. May GR, Gill MJ, Church DL, Sutherland LR. Gastrointestinal symptoms in ambulatory HIV-infected patients. Dig Dis Sci 1993; 38: 1388–94.

3. Bacellar H, Munoz A, Hoover DR, et al. for the Multicenter AIDS cohort study. Incidence of clinical AIDS conditions in a cohort of homosexual men with CD4+ cell counts < 100/mm³. J Infect Dis 1994; 170: 1284–7.

4. Watson A, Samore MH, Wanke CA. Diarrhea and quality of life in ambulatory HIV-infected patients. Dig Dis Sci 1996; 41: 1794–800.

5. Hoover DR, Saah AJ, Bacellar H, et al. for the Multicenter AIDS cohort study. Incidence of clinical AIDS conditions in a cohort of homosexual men with CD4+ cell counts < 100/mm³. J Infect Dis 1994; 170: 1284–7.

6. Selik RM, Chu SY, Ward JW. Trends in infectious diseases and cancers among persons dying of HIV infection in the United States from 1987 to 1992 Ann Intern Med 1995; 123: 933–6.

7. Weinert M, Grimes RM, Lynch DP. Oral manifestations of HIV infection. Ann Intern Med 1996; 125: 485–96.

8. Coleman DC, Bennett DE, Sullivan DJ, et al. Oral Candida in HIV infection and AIDS: New perspectives/new approaches. Crit Rev Microbiol 1993; 19: 61–82.

9. Wilcox CM, Straub RF, Clark WS. Prospective evaluation of topical clotrimazole troches. J Acquir Immune Defic Syndr 1993; 6: 1311–5.

10. DeWit SD, Weerts D, Goosens H, Clumeck N. Randomized comparison of oral fluconazole vs. clotrimazole troches for treatment of oral candidiasis in AIDS patients. Antimicrob Agents Chemother 1995; 42: 360–3.

11. Wilcox CM, Alexander LN, Clark WS, Thompson SE. Fluconazole compared with endoscopy for human immunodeficiency virus-infected patients with esophageal symptoms. Gastroenterology 1996; 110: 1169–77.

12. Koletar SL, Russell JA, Fass RJ, Plouffe JF. Comparison of oral flucytosine and intravenous clotrimazole troches as treatment of oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1990; 34: 2267–8.

13. Chavanet PY, Garry I, Charlier N, et al. for the Multicenter AIDS cohort study. Incidence of clinical AIDS conditions in a cohort of homosexual men with CD4+ cell counts < 100/mm³. J Infect Dis 1994; 170: 1284–7.

14. Laine L, Dretler RH, Conteas CN, et al. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial. Ann Intern Med 1992; 117: 655–60.

15. Wilcox CM, Alexander LN, Clark WS, Thompson SE. Fluconazole and clotrimazole troches as treatment of oral candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. Ital J Gastroenterol 1995; 27: 175–80.

16. Barbaro G, Barbarini G, Caladeron W, et al. Fluconazole vs. itraconazole for Candida esophagitis in acquired immunodeficiency syndrome. Gastroenterology 1996; 111: 1169–77.

17. Laine L, Rabeneck LR. Prospective study of fluconazole suspension for the treatment of oesophageal candidiasis in patients with AIDS. Aliment Pharmacol Ther 1995; 9: 553–6.

18. Barbaro G, Barbarini G, Mallegol I. Itraconazole oral solution (I) compared with fluconazole (F) for treatment of esophageal candidiasis. Proceedings of the XI International Conference on AIDS. Mo.B.116, 1996, p. 17.

19. Barbaro G, Barbarini G, Di Lorenzo G, Fluconazole vs. fluconazole in the treatment of esophageal candidiasis in AIDS patients: A randomized, placebo-controlled study. Endoscopy 1995; 27: 377–83.

20. Chavanet PY, Garry I, Charlier N, et al. Trial of glucose vs. fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. Br Med J 1992; 305: 921–5.

21. Joly V, Aubry P, Ndayiragide A, et al. Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or intralipid for the treatment of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1996; 23: 556–62.

22. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B. Recent progress and future directions. Clin Infect Dis 1996; 22(Suppl. 2): S133–44.
32 Dewsnup DH, Stevens DA. Efficacy of oral amphotericin B in AIDS patients with thrush clinically resistant to fluconazole. J Med Vet Mycol 1994; 32: 389–93.
33 Sandven P, Bjorneklett A, Mueland A, et al. Susceptibilities of Norwegian Candida albicans strains to fluconazole: emergence of resistance. Antimicrob Agents Chemother 1993; 37: 2443–8.
34 Bailey GG, Perry FM, Denning DW, Mandal BK. Fluconazole-susceptible and -resistant Candida albicans in vitro. Eur J Clin Microbiol Infect Dis 1994; 13: 455–62.
35 Law D, Moore CB, Wardle HM, Ganguli LA, Keaney MG, Denning DW. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chemother 1994; 34: 659–68.
36 Barchiesi F, Colombo AL, McGough DA, Fothergill AW, Rinaldi MG. Emergence of fluconazole-resistant and -susceptible Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994; 38: 1530–3.
37 Revankar SG, Kirkpatrick WR, McAtre RK, et al. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 174: 821–7.
38 Troillet N, Durussel C, Bille J, Clauser MP, Chave JP. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1993; 12: 911–5.
39 Maenza JR, Keruly JC, Moore RD, Chaissen RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173: 219–25.
40 Cameron ML, Schell WA, Bruch S, Bartlett JA, Waskin HA, Perfect JR. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type I. Antimicrob Agents Chemother 1993; 37: 2449–53.
41 Redding S, Smith J, Farinacci G, et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 1994; 18: 240–2.
42 Ruhnke M, Eigler A, Tennagen I, Gieseler B, Engelmann E, Trautmann M. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidiasis and human immunodeficiency virus infection. J Clin Microbiol 1994; 32: 2092–8.
43 Lacassin F, Domond F, Chochillon C, et al. Response to fluconazole by 23 patients with human immunodeficiency virus infection and oral candidiasis: Pharmacological and mycological factors. Antimicrob Agents Chemother 1996; 40: 1961–3.
44 Pfaffer MA, Rhine-Chalver J, Redding SW, et al. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol 1994; 32: 59–64.
45 Millon L, Mantleaux A, Rebourc G, et al. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: Persistence of Candida albicans strains with the same genotype. J Clin Microbiol 1994; 32: 1115–8.
46 Chavenet P, Lopez J, Grappin M, et al. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro–in vivo correlation in HIV-infected patients. AIDS 1994; 8: 945–50.
47 Le Guennec R, Reynes J, Mallic M, Pujol C, Janbon F, Bastide J. Fluconazole- and itraconazole-resistant Candida albicans strains from AIDS patients: multilocus enzyme electrophoresis analysis and antifungal susceptibilities. J Clin Microbiol 1995; 33: 2732–7.
48 He X, Tiballi RN, Zarins LT, et al. Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994; 38: 2495–7.
49 Heald AE, Cox GM, Schell WA, Bartlett Perfet JR. Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous vs. intermittent fluconazole therapy. AIDS 1996; 10: 263–8.
50 Powderly WG. Resistant candidiasis. AIDS Research Human Retrovir 1994; 10: 925–9.
51 Gallant JE, Moore RD, Chaissen RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 1994; 120: 932–44.
52 MacPheil LA, Hilton JF, Dodd CL, Greenspan D. Prophylaxis with nystatin pastilles for HIV-associated oral candidiasis. J Acquir Immune Defic Syndr Hum Retrovir 1996; 12: 470–6.
53 Just-Nubling G, Gentschaw G, Meissner K, et al. Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients. Eur J Clin Microbiol Infect Dis 1991; 10: 917–21.
54 Stevens DA, Greene SI, Lang OS. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex: randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily. Arch Intern Med 1991; 151: 2458–64.
55 Marriott DJE. Fluconazole once a week is secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients: A double-blind placebo-controlled study. Med J Aust 1993; 158: 312–6.
56 Leen CLS, Dunbar EM, Ellis ME, Mandal BK. Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study. J Infect 1990: 21: 55–60.
57 Powerdly WG, Finkelstein DM, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995; 332: 700–5.
58 Drew WL. Cytomegalovirus infections in patients with AIDS. Clin Infect Dis 1992; 14: 608–15.
59 Shepp DH, Moses JE, Kaplan MH. Seroepidemiology of cytomegalovirus in patients with advanced HIV disease: influence on disease expression and survival. J Acquir Immune Defic Syndr Hum Retrovir 1996; 11: 460–8.
Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1992; 166: 1223–7.

Goodgame RW, Genta RM, Estrada R, Demmler G, Buffone G. Frequency of positive tests for cytomegalovirus in AIDS patients: endoscopic lesions compared with normal mucosa. Am J Gastroenterol 1993; 88: 338–43.

Crumpacker CS, Ganciclovir. N Engl J Med 1996; 335: 721–9.

AIDS Research Group. Antiviral effects of foscarnet and ganciclovir therapy on human immunodeficiency virus p24 antigen in patients with AIDS and cytomegalovirus retinitis. J Infect Dis 1995; 172: 613–21.

Kaiser L, Perrin L, Hirschel B, et al. Foscarnet decreases human immunodeficiency virus RNA. J Infect Dis 1995; 172: 225–7.

Jacobson MA, O’Donnell JJ, Porteous D, Brodie HR, Feigal D, Mills J. Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome: Prevalence, natural history, and response to ganciclovir therapy. Q J Med 1988; 67: 473–86.

Buhles WC, Mastre BJ, Tinker AJ, et al. Ganciclovir activity and safety of cidofovir in patients with human immunodeficiency virus. Immune Defic Syndr 1992; 5: S11–7.

Chast F. Low plasma concentrations achieved with conventional schedules of administration of ganciclovir in patients with AIDS. J Infect Dis 1996; 174: 188–90.

Dieterich DT, Poles MA, Dicker M, Tepper R, Lew E. Foscarnet treatment of cytomegalovirus gastrointestinal infections in acquired immunodeficiency syndrome patients who have failed ganciclovir induction. Am J Gastroenterol 1993; 88: 542–8.

Dieterich DT, Poles MA, Lew EA, et al. Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. J Infect Dis 1993; 167: 1184–8.

Combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Studies of the Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Arch Ophthalmol 1996: 114: 23–33.

Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med. 1996; 334: 1491–7.

Wilcox CM, Schwartz DA, Clark WS. Causes, response to therapy, and long-term outcome of esophageal ulcer in patients with human immunodeficiency virus infection. Ann Intern Med 1995; 122: 143–9.

Bagdades EK, Pillay D, Squire SB, O’Neil C, Johnson MA, Griffiths PD. Relationship between herpes simplex virus ulceration and CD4+ cell counts in patients with HIV infection. AIDS 1992; 6: 1317–20.

Genereau T, Lortholary O, Bouchaud O, et al. Herpes simplex esophagitis in patients with AIDS: Report of 34 cases. Clin Infect Dis 1996; 22: 926–31.

Laskin OL. Clinical pharmacokinetics of acyclovir. Clin Pharmacokinet 1983; 8: 187–201.

Palu G, Gerna G, Bevilacqua F, Marcello A. A point mutation in the thymidine kinase gene is responsible for acyclovir-resistance in herpes simplex virus type 2 sequential isolates. Virus Res 1992; 25: 133–44.

Lauber DS, Starr SE. Resistance to antivirals. Pediatr Clin N Am 1995; 42: 583–99.

Balfour HH, Jr, Benson C, Braun J, et al. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr 1994; 7: 254–60.

Safiri S, Kemmerly S, Plotkin B, et al. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J Infect Dis 1994; 169: 193–6.

Kitchen VS, Helbert M, Francis ND, et al. Epstein–Barr virus associated oesophageal ulcers in AIDS. Gut 1990; 31: 1223–5.

Cunningham AL, Grobman GS, Harkness J, et al. Gastrointestinal viral infections in homosexual men who were asymptomatic and seropositive for human immunodeficiency virus. J Infect Dis 1988; 158: 386–91.

Janoff EN, Orenstein JM, Manischewitz JF, Smith PD. Adenovirus colitis in the acquired immunodeficiency syndrome. Gastroenterology 1991; 100: 976–9.
Rhode M, Flanigan T, Carey J, et al. Enteric viruses and diarrhea in HIV-infected patients. N Engl J Med 1993; 329: 14–20.

Schmidt W, Schneider T, Heise W, et al. Stool viruses, infections, and diarrhea in HIV-infected patients. J Acquir Immune Defic Syndr Human Retrovir 1996; 12: 33–8.

Tesson HS, Godwin TA, Ramirez EA. Cryptosporidiosis of the biliary tract in AIDS. Radiology 1991; 180: 51–6.

Bouche H, Housset C, Dumont JL, et al. AIDS-related cholangitis: diagnostic features and course in 15 patients. J Hepatol 1993; 17: 34–9.

Connolly GM, Dryden MS, Shanson DC, Gazzard BG. Cryptosporidial diarrhea in AIDS and its treatment. Gut 1988; 29: 593–7.

Goldstein ST, Juranek DD, Ravenholt O, et al. Cryptosporidiosis: An outbreak associated with drinking water despite state-of-the-art water treatment. Ann Intern Med 1996; 124: 459–68.

Vakil NB, Schwartz SM, Buggy BP, et al. Biliary cryptosporidiosis in HIV-infected people after the waterborne outbreak of cryptosporidiosis in Milwaukee. N Engl J Med 1996; 334: 19–23.

McGowan I, Hawkins AS, Weller IVD. The natural history of cryptosporidiosis in HIV-infected patients. AIDS 1993; 7: 349–54.

Flanigan T, Whalen C, Turner J, et al. Cryptosporidium infection and CD4 counts. Ann Intern Med 1992; 116: 840–2.

Goodgame RW, Kimball K, Ou CN, et al. Intestinal function and injury in acquired immunodeficiency syndrome-related cryptosporidiosis. Gastroenterology 1995; 108: 1075–82.

Armitage K, Flanigan T, Carey J, et al. Treatment of cryptosporidiosis with paromomycin. Arch Intern Med 1992; 152: 2497–9.

Greenberg RE, Mir R, Bank S, Siegal FP, Resolution of intestinal cryptosporidiosis after treatment of AIDS with AZT. Gastroenterology 1989; 97: 1327–30.

Simon D, Weiss L, Tunowitiz HB, Wittner M. Resolution of Cryptosporidium infection in an AIDS patient after improvement of nutritional and immune status with octreotide. Am J Gastroenterol 1991; 86: 615–8.

Shield J, Melville C, Novelli V, et al. Bovine colostrum immunoglobulin concentrate for cryptosporidiosis in AIDS. Arch Dis Child 1993; 69: 451–3.

Heaton P. Bovine colostrum immunoglobulin concentrate for cryptosporidiosis in AIDS. Arch Dis Child 1994; 70: 356–7.

Greenberg PD, Cello JP. Treatment of severe diarrhea caused by Cryptosporidium parvum with oral bovine immunoglobulin concentrate in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovir 1996; 13: 348–54.

Loeb M, Walach C, Phillips J, et al. Treatment with letrazuril of refractory cryptosporidial diarrhea complicating AIDS. J Acquir Immune Defic Syndr Hum Retrovir 1995; 10: 48–53.

Harris M, Deutsch G, MacLean JD, Tsoukas CM. A phase I study of letrazuril in AIDS-related cryptosporidiosis. AIDS 1994; 8: 1109–13.

Bissuel F, Cotte L, de Montcolos M, Rabodonirina M, Trepo C. Absence of systemic absorption of oral paromomycin during long-term, high-dose treatment for cryptosporidiosis in AIDS. J Infect Dis 1994; 170: 749–50.

Marshall RJ, Flanigan TP. Paromomycin inhibits Cryptosporidium infection of a human enterocyte cell line. J Infect Dis 1992; 165: 772–4.

Cirioni O, Giacometto A, Balducci M, Drenaggi D, Del Prete MS, Scalise G. Anticryptosporidial activity of paromomycin. J Infect Dis 1995; 172: 1169–70.

Clezy K, Gold J, Jones P. Paromomycin for the treatment of cryptosporidial diarrhoea in AIDS patients. AIDS 1991; 5: 1146–7.

Bissuel F, Cotte L, Rabodonirina M, Rougier P, Piens M-A, Trepo C. Paromomycin: an effective treatment for cryptosporidial diarrhea in patients with AIDS. Clin Infect Dis 1994; 18: 447–9.

Scaglia M, Atzori C, Marchetti G, Orso M, Maserati R, Oruni A. Effectiveness of aminosidine (paromomysin) sulfate in chronic Cryptosporidium diarrhea in AIDS patients: An open, uncontrolled, prospective clinical trial. J Infect Dis 1994; 170: 1349–50.

White AC, Chappell CL, Hayat CS, Kimball KT, Flanigan TP. Goodgame RW. Paromomycin for cryptosporidiosis in AIDS: A prospective, double-blind trial. J Infect Dis 1994; 170: 419–24.

Molina JM, Surfati C, Beauvais B, et al. Intestinal microsporidiosis in human immunodeficiency virus-infected patients with chronic unexplained diarrhea: Prevalence and clinical and biologic features. J Infect Dis 1993; 167: 217–21.

Kotler DP, Orenstein JM. Prevalence of intestinal microsporidiosis in HIV-infected patients referred for gastroenterological evaluation. Am J Gastroenterol 1994; 89: 1998–2002.

Pol S, Romana CA, Richard S, et al. Microsporidia infection in patients with the human immunodeficiency virus and unexplained cholangitis. N Engl J Med 1993; 328: 95–9.

Weber R, Bryan RT, Schwartz DA, Owen RL. Human microsporidial infections. Clin Microbiol Rev 1994; 7: 426–61.

Goodgame RW. Understanding intestinal spore-forming protozoa: Cryptosporidium, microsporidia, isospora, and cyclospora. Ann Intern Med 1996; 124: 429–41.

Asmuth DM, DeGirolami PC, Federman M, et al. Clinical features of microsporidiosis in patients with AIDS. Clin Infect Dis 1994; 18: 819–25.

Kotler DP, Giang TT, Garro ML, Orenstein JM. Light microscopic diagnosis of microsporidiosis in patients with AIDS. Am J Gastroenterol 1994; 89: 540–4.

Weber R, Bryan RT, Owen RL, Wilcox CM, Gorenkin L, Visvesvara GS. Improved light-microscopical detection of microsporidia spores in stool and duodenal aspirates. N Engl J Med 1992; 326: 161–6.

© 1997 Blackwell Science Ltd, Aliment Pharmacol Ther 11, 425–443
126 Eeftinck Schattenkerk JKM, van Gool T, van Ketel RJ, et al. Clinical significance of small-intestinal microsporidiosis in HIV-1-infected individuals. Lancet 1991; 337: 895–8.
127 Dore GJ, Marriott DJ, Hing MC, Hankness JL, Field AS. Disseminated microsporidiosis due to Septata intestinalis in nine patients infected with the human immunodeficiency virus: Response to therapy with albendazole. Clin Infect Dis 1995; 21: 70–6.
128 Anwar-Bruni DM, Hogan SE, Schwartz DA, Wilcox CM, Bryan RT, Lennox JL. Atovaquone is effective treatment for the symptoms of gastrointestinal microsporidiosis in HIV-1 infected patients. AIDS 1996; 10: 619–24.
129 Dieterich DT, Lew EA, Kotler DP, Poles MA, Orenstein JM. Treatment with albendazole for intestinal disease due to Enterocytozoon bieneusi in patients with AIDS. J Infect Dis 1994; 169: 178–83.
130 Molina JM, Oksenhendler E, Beauvais B, et al. Disseminated microsporidiosis due to Septata intestinalis in patients with AIDS. Clinical features and response to albendazole therapy. J Infect Dis 1995; 171: 245–9.
131 Soave R. Cyclospora: An overview. Clin Infect Dis 1996; 23: 429–37.
132 Pape JW, Verdier R-I, Boncy M, Boncy J, Johnson WD. Cyclospora infection in adults infected with HIV: Clinical manifestations, treatment, and prophylaxis. Ann Intern Med 1994; 121: 654–7.
133 Farthing MJG. Giardiasis. Gastroenterol Clin North Am 1988; 94: 984–93.
134 Jessurun J, Barron-Rodriquez LP, Fernandez-Tinoco G, Herzenberg LA, Moore CA, et al. Disseminated Mycobacterium avium-intracellulare complex bacteremia. J Infect Dis 1994; 170: 1601–5.
135 Torriani F, McCutchan JA, Boffi A, Kraus MR, Hovhannessian LA, Havlir DV. Autopsy findings in AIDS patients with Mycobacterium avium complex bacteremia. J Infect Dis 1994; 170: 1601–5.
136 Farhi DC, Mason UG, Horsburgh CR. Pathologic findings in disseminated Mycobacterium avium-intracellulare infection. Am J Clin Pathol 1986; 85: 67–72.
137 Benson C. Disseminated Mycobacterium avium-intracellulare complex in patients with AIDS. AIDS Res Hum Retroviruses 1994; 10: 913–6.
138 Kemper CA, Meng T-C, Nussbaum J, et al. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen: Rifabutin, ethambutol, clofazimine, and ciprofloxacin. Ann Intern Med 1994; 121: 466–72.
139 Benson C. Disseminated Mycobacterium avium complex disease in patients with AIDS. AIDS Res Hum Retroviruses 1994; 10: 913–6.
140 Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: A randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994; 121: 905–11.
141 Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992; 165: 1082–5.
142 Chaisson RE, Moore RD, Richman DD, Keruly J, Creugh T. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. Am Rev Respir Dis 1992; 146: 285–9.
143 Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996; 124: 633–42.
144 Lanjee SW, Anand BS, Genta R, et al. Major differences in the spectrum of gastrointestinal infections associated with AIDS in India vs. the west: An autopsy study. Clin Infect Dis 1996; 23: 482–5.
145 Gray JR, Rabeneck L. Atypical mycobacterial infection of the gastrointestinal tract in AIDS patients. Am J Gastroenterol 1989; 84: 1521–4.
146 Greene JB, Sidhu GS, Lewin S, et al. Mycobacterium avium-intracellulare: a cause of disseminated life-threatening infection in homosexuals and drug abusers. Ann Intern Med 1982; 97: 539–46.
147 Trepo C. Prevalence of intestinal protozoans in French patients. J Infect Dis 1992; 146: 285±9.
148 Farthing MJG. Giardiasis. Gastroenterol Clin North Am 1988; 94: 984±93.
149 Moore RD, Chaisson RE, Richman DD, Keruly J, Creugh T. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. Am Rev Resp Dis 1992; 146: 285–9.
150 Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: A randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994; 121: 905–11.
151 Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: A randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994; 121: 905–11.
152 Kemper CA, Meng T-C, Nussbaum J, et al. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen: Rifabutin, ethambutol, clofazimine, and ciprofloxacin. Ann Intern Med 1992; 116: 466–72.
153 Benson C. Disseminated Mycobacterium avium complex disease in patients with AIDS. AIDS Res Hum Retroviruses 1994; 10: 913–6.
154 Kemper CA, Meng T-C, Nussbaum J, et al. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen: Rifabutin, ethambutol, clofazimine, and ciprofloxacin. Ann Intern Med 1992; 116: 466–72.
155 Shafran SD, Singer J, Zarowny DP, et al. Incidence and natural history of Mycobacterium avium complex disease treated with zidovudine. Am Rev Resp Dis 1992; 146: 285–9.
156 Marshall JB. Tuberculosis of the gastrointestinal tract and peritoneum. Am J Gastroenterol 1993; 88: 989–99.
157 Nightengale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993; 329: 828–33.

158 Masur H. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. N Engl J Med 1993; 329: 898–904.

159 Pierce M, Crampton S, Henry D, et al. Risk factors for Campylobacter jejuni infection in hospital newborns. J Pediatr 1993; 123: 835–40.

160 Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996; 335: 392–8.

161 Smith PD, Lane HC, Gill VJ, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335: 384–91.

162 Smith PD, Macher AM, Bookman MA, et al. Multicentre trial of octreotide in patients infected with the human immunodeficiency virus. J Clin Gastroenterol 1992; 15: 284–90.

163 Smith PD, Eisner MS, Manischewitz JF, Gill VJ, Masur H, Fox CF. Esophageal disease in AIDS is associated with pathologic processes rather than mucosal human immunodeficiency virus type 1. J Infect Dis 1993; 167: 547–52.

164 Rene E, Marche C, Regnier B, et al. Multicentre trial of octreotide in patients with refractory AIDS-associated diarrhea. J Clin Endocrinol Metab 1994; 89: 2163–7.

165 Nelson MR, Cello JP, Grendell JH, Basuk P, et al. Review article: antidiarrhoeal pharmacology and therapeutics. Aliment Pharmacol Ther 1995; 9: 87±106.

166Rodriguez LP, Cello JP, Grendell JH, Basuk P, et al. Multicenter trial of octreotide in patients with refractory AIDS-associated diarrhea. J Clin Gastroenterol 1994; 19: 209–14.

167 Kotler DP, Reka S, Orenstein JM, Fox CH. Chronic idiopathic esophageal ulceration in the acquired immunodeficiency syndrome. J Clin Gastroenterol 1992; 15: 284–90.

168 Manabe YC, Vinetz JM, Moore RD, Merz C, Charache P, Bartlett GJ. Clostridium difficile colitis: An efficient clinical approach to diagnosis. Ann Intern Med 1995; 123: 835–40.

169 Lu SS, Schwartz JM, Simon DM, Brandt LJ. Clostridium difficile-associated diarrhea in patients with HIV positivity and AIDS: a prospective controlled study. Am J Gastroenterol 1994; 89: 1226–9.

170 Rabeneck L, Popovic M, Gartner S, et al. Acute HIV infection presenting with painful swallowing and esophageal ulcers. J Am Med Assoc 1990; 263: 2318–22.

171 Jallon JM, Sitten JE, Hammer RA, Agrawal NM, Ertan A, Muhatma M. HIV-1 gp41 antigen demonstration in esophageal ulcers with acquired immunodeficiency syndrome. J Clin Gastroenterol 1991; 13: 664–8.